Interleukin-13 (Cynomolgus monkey) (IL-13)

Interleukin-13 (IL-13) is a critical Th2-cell-derived cytokine that serves as a central mediator in the pathophysiology of allergic inflammation and asthma. In cynomolgus monkeys (Macaca fascicularis), IL-13 exhibits high sequence homology and functional similarity to human IL-13, making it a vital target for preclinical evaluation of therapeutic antibodies (UniProt Q864V6). The cytokine exerts its biological effects by binding to a heterodimeric receptor complex consisting of IL-13 receptor alpha 1 (IL-13Ra1) and IL-4 receptor alpha (IL-4Ra), which triggers the JAK/STAT6 signaling pathway. This activation leads to key features of Type 2 immunity, including the induction of IgE secretion by B cells, goblet cell hyperplasia, and increased airway smooth muscle contractility. Drugs such as lebrikizumab and tralokinumab are designed to bind and neutralize IL-13 directly, while others like dupilumab target the shared IL-4Ra subunit to block both IL-4 and IL-13 signaling. These therapies have shown significant clinical efficacy in treating moderate-to-severe asthma and atopic dermatitis by reducing airway inflammation and skin lesions.

Other names

IL13NC30ALRHBHR1P600Interleukin 13

Neutralization of the IL-13 cytokine to prevent binding to the IL-13Ra1/IL-4Ra receptor complex, thereby inhibiting downstream STAT6 signaling and Th2-mediated inflammation.